Monoclonal antibodies against IL-17A or IL-17RA have shown promise in reducing inflammation and bone loss in various autoimmune diseases, such as psoriatic arthritis (106), ankylosing spondylitis (107) and rheumatoid arthritis (108). The gene discussed is IL17A; the disease is ankylosing spondylitis.